SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing massive volatility as investors aggressively debate whether the stock is trapped in a manufactured short squeeze or beginning a long-overdue collapse. The community remains deeply divided, with some betting on further parabolic gains driven by institutional float concentration, while others warn of a looming crash as the company faces high debt and potential share dilution.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as investors react to a new share dilution program and the acquisition of the UK-based Lyphe Group, while the community remains hyper-focused on the potential for cannabis rescheduling to Schedule III to act as a major sector catalyst. The stock continues to see intense debate between bulls anticipating a policy-driven breakout and bears critical of management's consistent use of equity offerings to fund growth.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is experiencing a surge in trading volume and bullish sentiment as investors eye a breakout toward the $300 level, driven by strong AI infrastructure demand and potential hyperscaler partnership expectations ahead of earnings. While many in the community celebrate the rapid climb as a sign of institutional strength, others warn of technical overextension and potential volatility as the stock enters high-momentum 'FOMO' territory.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

The cannabis sector is seeing renewed momentum driven by heightened speculation around imminent federal rescheduling as the Biden administration faces mounting pressure to deliver on previous policy commitments. Investors are actively debating the timing of potential catalysts while monitoring institutional activity, with many betting that increased political focus around the 4/20 holiday and upcoming midterms will force an acceleration of the regulatory process.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing a high-velocity rally fueled by its inclusion in the Nasdaq-100, which has triggered mandatory institutional buying, alongside robust AI-driven demand for NAND memory. The community remains heavily focused on potential stock split announcements and explosive short-squeeze potential, with many traders debating whether the current momentum will sustain as they watch for key resistance levels ahead of upcoming earnings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending due to frustration among traders witnessing an relentless, multi-week melt-up in semiconductor indices that has triggered significant losses for those betting against the sector. The community is actively debating whether the persistent rally is driven by genuine AI-sector demand or extreme market manipulation, while many weigh the risks of holding highly leveraged instruments that face continuous decay.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmax Inc (NMAX) is experiencing intense volatility and heightened trading activity as retail investors weigh in on its potential as a short squeeze candidate, drawing frequent comparisons to other meme-stock movements. While some community members are bullish on the stock's growth potential and institutional interest, others are actively debating its fundamental value and the influence of short-selling dynamics, keeping the ticker at the center of ongoing market speculation.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as momentum builds following management's firm rebuttal of short-seller claims and the disclosure of key partnerships, including orders linked to Marvell Technology. Investors are actively discussing a potential re-rating as the company shifts from R&D to commercial scaling, fueling a massive spike in trading volume and bullish options activity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing a historic rally, driven by intense investor FOMO and robust demand for semiconductor chips tied to the AI sector. The community is sharply divided between bulls riding the massive momentum toward potential triple-digit levels and bears who are warning of extreme overextension and imminent volatility decay.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is generating significant community buzz as investors closely watch the R2 SUV production ramp and the company's expansion into energy storage partnerships with Redwood Materials. Traders are actively debating the stock's potential for a breakout, driven by anticipation surrounding upcoming earnings and the strategic scaling of manufacturing capabilities despite persistent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy

Wall Street Zen raised Xilio Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday...

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.

Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8% - What's Next?

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 4.8% - What's Next...

Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume - Here's What Happened

Xilio Therapeutics (NASDAQ:XLO) Sees Strong Trading Volume - Here's Why...

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Xilio Therapeutics ended nearly 8% higher on Tuesday after the company reported positive early trial results for its cancer drug XTX301, began dosing patients in Phase 2, and secured a $17.5 million milestone payment from Gilead Sciences.Xilio said Phase 1 data for XTX301, a tumor-activated IL-12 therapy, showed anti-tumor activity in patients with advanced solid tumors, including two partial responses, while most side effects were mild or moderate.&nbsp;The treatment also sustained interferon gamma signaling across cycles, supporting the company’s approach of reprogramming “cold” tumors into inflamed “hot” ones.Based on the findings, Xilio selected a recommended Phase 2 dose and schedule and has begun treating patients in the Phase 2 portion of its ongoing Phase 1/2 trial in the U.S, which will enroll about 40 participants.&nbsp;Enrollment in Phase 1A has been completed, and Phase 1B expansion is still underway.The milestone payment from Gilead, tied to the start of Phase 2, extends Xilio’s cash runway into the first quarter of 2027. As of June 30, the company held $121.6 million in cash and equivalents and expects to receive the Gilead payment in the fourth quarter of 2025.Under their March 2024 global license agreement, Gilead may take over development and commercialization of XTX301 after reviewing clinical data, with an option fee of $75 million.&nbsp;Xilio could receive up to $500 million in additional development, regulatory and sales milestones, plus tiered royalties ranging from high single digits to mid-teens on global net sales.On Stocktwits, retail sentiment for Xilio was ‘bullish’ amid a 2,333% surge in 24-hour message volume.One user said that the stock had “solid news” but needed more trading volume to push through the $0.80 level.<stembedurl>https://stocktwits.com/MrTicker/message/627979369</stembedurl>Another user predicted the shares would climb quickly, noting it was “super hard to get shares.”&nbsp;They highlighted that Xilio held about $140 million in cash against a roughly $38 million market cap, arguing the market had assigned little to no value to its partnerships, assets, or even its cash balance, and suggesting a reprice was likely.<stembedurl>https://stocktwits.com/SteadyTrade55/message/627979366</stembedurl><a href="https://stocktwits.com/symbol/XLO">Xilio’s stock</a> has declined 21.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Xilio’s stock has declined 21.5% so far in 2025. (Photo credit: Getty Images)

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.

Equity

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Xilio Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $TSLA earnings after the close?

Current Price	$8.43
Prev Close	$8.52
Open	$8.63
Dividend Yield	0.00%
50-Day Moving Average	$7.98
Beta	0.75
Avg. Volume	48,020.34
PE Ratio	-1.53

52-Week High	$16.52
52-Week Low	$6.47
Market Capitalization	$49.27M
EPS (Annual)	-$4.19
Price to Book	1.09
Revenue Per Employee	$575,868.42

XLO
Xilio Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest XLO News

XLOXilio Therapeutics Inc